ICG Distribution in Breast Cancer Margins

Phase 2, open-label, single-arm trial of indocyanine green in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Evaluation of the ability of NIR imaging to show (fluorescent) the tumoral volumes, the tumoral tissues to be analyzed by the pathologist, especially at the level of the operative margins at 17 months. Started Jan 2014; status: completed.